What is StrideBio?
StrideBio is a biotechnology company dedicated to developing innovative gene therapies. Leveraging its proprietary STRIVE Capsid Platform and robust AAV manufacturing capabilities, the company focuses on creating effective treatments for individuals with severe and life-threatening conditions. StrideBio's commitment to scientific excellence and integrity drives its mission to translate cutting-edge research into life-enhancing and life-extending therapies.
How much funding has StrideBio raised?
StrideBio has raised a total of $97.2M across 2 funding rounds:
Series A
$15.7M
Series B
$81.5M
Series A (2018): $15.7M with participation from Hatteras Venture Partners, Takeda Ventures, UCB Ventures, and Alexandria Venture Investments
Series B (2021): $81.5M led by Novo Holdings, Caas Capital Management, Octagon Capital, Pontifax, Sarepta Therapeutics, UF Innovate Ventures, and Northpond Ventures
Key Investors in StrideBio
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm specializing in transformative companies within the biotech, MedTech, and HealthTech sectors, providing capital and strategic support to innovative healthcare solutions.
Takeda Ventures
Takeda Ventures, part of Takeda Pharmaceutical Company, focuses on pharmaceutical products across various therapeutic areas including oncology, neuroscience, and rare diseases, aiming to advance human medicine.
Pontifax
Pontifax Venture Capital is dedicated to groundbreaking innovations in life sciences, actively investing in and building transformative healthcare technology companies from early-stage research to growth phases.
What's next for StrideBio?
The substantial enterprise-level funding, particularly the recent strategic investment, positions StrideBio for accelerated growth and pipeline expansion. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and potentially support clinical trials. The company's focus on gene therapy for rare and severe diseases suggests a strategic direction towards addressing unmet medical needs, with future developments likely centered on advancing their therapeutic candidates through regulatory pathways and towards commercialization.
See full StrideBio company page
